Summary
Theoretically the effect of the β-blocking agent alprenolol might be reinforced by concomitant administration of salicylate, as both drugs are partly excreted as glucuronides and both appear to have a saturable mechanism for biotransformation. The β-blocking effect of alprenolol administered alone and with sodium salicylate has been compared by studying the inhibition of the hemodynamic response to physical work. Blood samples were collected immediately after exercise and the serum analysed for unchanged alprenolol. The urinary excretion of alprenolol, alprenolol glucuronide and salicylate and its metabolites was followed for more than 24 h. The administration of sodium salicylate did not influence significantly the pharmacological effect of alprenolol or its serum levels or half life, nor did it affect the formation of alprenolol glucuronide. The latter drug did not affect the metabolism of salicylate. These results show that therapeutic doses of alprenolol and salicylate are unlikely to give any interaction of clinical importance.
Similar content being viewed by others
References
Åblad, B., Ervik, M., Hallgren, J., Johnsson, G., Sölvell, L.: Pharmacological effects and serum levels of orally administered alprenolol in man. Europ. J. clin. Pharmacol.5, 44–52 (1972).
Ervik, M.: Gaschromatographic determination of the secondary amine alprenolol, as its trifluoroacetyl derivative, at nanogram levels in biological fluids. Acta Pharm. Suecica6, 393–400 (1969).
Johansson, R., Borg, K.-O., Obianwu, H.O., Bodin, N.-O., Svensson, R.: Absorption, distribution and excretion of 1-(o-allylphenoxy)-3-isopropylamino-2-propanol (alprenolol) in human subjects, dogs and rats. In the press 1973.
Johansson, R., Regårdh, C.G., Sjögren, J.: Absorption of alprenolol in man from tablets with different rates of release. Acta Pharm. Suecica8, 59–70 (1971).
Johnsson, G., Norrby, A., Sölvell, L.: Potency and time-effect relationship in man of propranolol and H 56/28. Acta Pharmacol. Toxicol.25, Suppl. 2, 95–105 (1967).
Johnsson, G., Sjögren, J., Sölvell, L.: Beta-blocking effect and serum levels of alprenolol in man after administration of ordinary and sustained release tablets. Europ. J. clin. Pharmacol.3, 74–81 (1971).
Levy, G., Prochnal, J.A.: Drug biotransformation interactions in man I: Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man. J. Pharm. Sci.57, 1330–1335 (1968).
Levy, G., Regårdh, C.G.: Drug biotransformation interactions in man. V: Acetaminophen and salicylic acid. J. Pharm. Sci.60, 608–611 (1971).
Levy, G., Tsuchiya, T., Amsel, P.: Limited capacity for salicylglucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin. Pharmacol. Ther.13, 258 (1972).
Woolf, C.M.: Principles of Biometry, p. 203. Princeton, New Jersey, Toronto, London, Melbourne: D. van Nostrand Company Inc. 1968.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnsson, G., Regårdh, C.G. & Sölvell, L. Lack of biological interaction of alprenolol and salicylate in man. Eur J Clin Pharmacol 6, 9–14 (1973). https://doi.org/10.1007/BF00561794
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00561794